Bicycle Therapeutics Dividend
Dividend criteria checks 0/6
Bicycle Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$4.23 |
| Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19
Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year
Jan 19Bicycle Therapeutics gives out pipeline update, shares rise
Jan 14What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?
Dec 15Bicycle Therapeutics settles IP dispute with Pepscan
Nov 30Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BCYC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCYC's dividend payments have been increasing.
Dividend Yield vs Market
| Bicycle Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BCYC) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (BCYC) | n/a |
Notable Dividend: Unable to evaluate BCYC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCYC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BCYC's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BCYC has not reported any payouts.